This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2018 Jan;160(1):43-46.

doi: 10.1007/s15006-018-0091-2.

[PCSK9 inhibitors: For which patients? For which indication? What to consider?]

[Article in German]

Kristina Busygina¹, Klaus G Parhofer²

Affiliations

Affiliations

¹ Klinikum der Universität München, Medizinische Klinik und Poliklinik IV - Großhadern, Marchioninistr. 15, D-81377, München, Deutschland. kristina.busygina@med.uni-muenchen.de.
² Klinikum der Universität München, Medizinische Klinik und Poliklinik IV - Großhadern, Marchioninistr. 15, D-81377, München, Deutschland.

PMID: 29335943
DOI: 10.1007/s15006-018-0091-2

Review

[PCSK9 inhibitors: For which patients? For which indication? What to consider?]

[Article in German]

Kristina Busygina et al. MMW Fortschr Med. 2018 Jan.

. 2018 Jan;160(1):43-46.

doi: 10.1007/s15006-018-0091-2.

Authors

Kristina Busygina¹, Klaus G Parhofer²

Affiliations

¹ Klinikum der Universität München, Medizinische Klinik und Poliklinik IV - Großhadern, Marchioninistr. 15, D-81377, München, Deutschland. kristina.busygina@med.uni-muenchen.de.
² Klinikum der Universität München, Medizinische Klinik und Poliklinik IV - Großhadern, Marchioninistr. 15, D-81377, München, Deutschland.

PMID: 29335943
DOI: 10.1007/s15006-018-0091-2

No abstract available

Keywords: PCSK9 antibodies; PCSK9 inhibitors; alirocumab; evolocumab.

PubMed Disclaimer

Similar articles

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K, Sharma M, Ferdinand KC. Yadav K, et al. Nutr Metab Cardiovasc Dis. 2016 Oct;26(10):853-62. doi: 10.1016/j.numecd.2016.05.006. Epub 2016 May 30. Nutr Metab Cardiovasc Dis. 2016. PMID: 27352986 Review.
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
Blom DJ, Dent R, Castro RC, Toth PP. Blom DJ, et al. Vasc Health Risk Manag. 2016 May 9;12:185-97. doi: 10.2147/VHRM.S102564. eCollection 2016. Vasc Health Risk Manag. 2016. PMID: 27274264 Free PMC article. Review.
A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases.
Chen B, Shi X, Cui Y, Hou A, Zhao P. Chen B, et al. Curr Top Med Chem. 2019;19(20):1790-1817. doi: 10.2174/1568026619666190809094203. Curr Top Med Chem. 2019. PMID: 31400268 Review.
The efficacy of anti-PCSK9 antibodies: Results from recent trials.
Gouni-Berthold I. Gouni-Berthold I. Atheroscler Suppl. 2017 Nov;30:9-18. doi: 10.1016/j.atherosclerosissup.2017.05.030. Epub 2017 Jun 1. Atheroscler Suppl. 2017. PMID: 29096867 Review.
Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
Arca M. Arca M. Atherosclerosis. 2017 Jan;256:134-145. doi: 10.1016/j.atherosclerosis.2016.09.001. Epub 2016 Sep 2. Atherosclerosis. 2017. PMID: 27993383 Review.

See all similar articles

Cited by

Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia).
Waldmann E, Wu L, Busygina K, Altenhofer J, Henze K, Folwaczny A, Parhofer KG. Waldmann E, et al. PLoS One. 2022 Mar 23;17(3):e0265838. doi: 10.1371/journal.pone.0265838. eCollection 2022. PLoS One. 2022. PMID: 35320320 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal